Emyria Limited (ASX: $EMD) has been chosen as a key trial site for the 'IMPACT-2' trial, sponsored by Transcend Therapeutics, to evaluate the safety and efficacy of methylone in treating PTSD. The trial will be conducted at Emyria's newly inaugurated Empax Centre, showcasing the company's advanced research capabilities and infrastructure.
Dr. Michael Winlo, CEO of Emyria, expressed his delight in collaborating with Transcend Therapeutics on the trial, highlighting the company's dedication to bringing new treatments to patients and utilizing the full capabilities of the Empax Centre. The selection of the Empax Centre as an international trial site recognizes the team's unique capabilities, demonstrating Emyria's commitment to advancing mental health outcomes for patients with severe PTSD.
Emyria's Empax Centre has been selected for the 'IMPACT-2' trial, emphasizing the company's expertise in psychological trauma care and clinical trial delivery. The trial aims to investigate the effects of methylone on neuroplasticity and PTSD symptoms, aligning with Emyria's mission to develop innovative treatments for mental health conditions. If the trial proceeds as planned, Emyria expects to competitively recruit at least 20 participants and provide comprehensive specialist mental health services. This opportunity underscores Emyria's leadership in mental health innovation and its commitment to maximizing the potential of its unique facilities and capabilities.